To the full analysis
Sopharma AD stock: growth
SPH.WASopharma AD reported BGN 2.61B in revenue for fiscal 2025, up 22.6% on the prior year, up 12.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
10.5%
per year from 2011 to 2025, per share 3.1%
Earnings (Annual rate)
9.3%
per year from 2011 to 2025, per share 1.9%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2011 | |
|---|---|---|---|
| Revenue | 12.6% | 11.5% | 10.5% |
| Revenue per share | −7.8% | 1.2% | 3.1% |
| Earnings | 35.0% | 20.1% | 9.3% |
| Earnings per share | 10.2% | 8.7% | 1.9% |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2011 | $644.73M | $38.4M | −$2.56M |
| 2012 | $688.58M | $35.2M | −$28.24M |
| 2013 | $762.69M | $29.25M | −$7.71M |
| 2014 | $840.52M | $20.18M | −$5.9M |
| 2015 | $874.98M | $21.31M | −$1.27M |
| 2016 | $877.09M | $50.64M | $32.41M |
| 2017 | $1.02B | $40M | $17.47M |
| 2018 | $1.18B | $28.34M | $501K |
| 2019 | $1.28B | $86.99M | −$168.48M |
| 2020 | $1.44B | $29.81M | −$206.42M |
| 2021 | $1.6B | $89.5M | −$103.07M |
| 2022 | $1.66B | $71.12M | $101.4M |
| 2023 | $1.89B | $95.21M | $1.75M |
| 2024 | $2.13B | $76.31M | −$44.66M |
| 2025 | $2.61B | $133.52M | −$124.29M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = PLN 3.9742)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 14 Aug 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.